News

Captor Therapeutics has selected ICON as the CRO company to conduct the first phase of clinical trials under the CT-01 project

Captor Therapeutics will raise PLN 40 million from share issue for implementation of strategic goals

Captor Therapeutics appoints Wedbush as its exclusive strategic financial advisor and establishes relationship with MSQ Ventures in China

Captor Therapeutics publishes financial report for the first half of 2023

Captor Therapeutics with PLN 52.2 million co-funding from The Medical Research Agency of Poland

Captor Therapeutics publishes Q1 2023 financial results

Captor Therapeutics has published its 2022 report. The past year was a period of dynamic growth for the Company in both science and business.

Captor Therapeutics Discloses Molecular Targets of Pipeline’s Lead Assets and Invites Stakeholders to Webcast